Verve Therapeutics Inc (VERV)
6.005
-0.36
(-5.73%)
USD |
NASDAQ |
May 10, 16:00
6.005
0.00 (0.00%)
After-Hours: 19:35
Verve Therapeutics Cash from Operations (Quarterly): -43.08M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -43.08M |
| December 31, 2023 | -40.68M |
| September 30, 2023 | -11.81M |
| June 30, 2023 | -47.96M |
| March 31, 2023 | -49.10M |
| December 31, 2022 | -32.89M |
| September 30, 2022 | -29.18M |
| June 30, 2022 | -26.76M |
| March 31, 2022 | -33.51M |
| Date | Value |
|---|---|
| December 31, 2021 | -28.04M |
| September 30, 2021 | -21.36M |
| June 30, 2021 | -13.34M |
| March 31, 2021 | -15.14M |
| December 31, 2020 | -14.98M |
| September 30, 2020 | -6.324M |
| June 30, 2020 | -7.144M |
| March 31, 2020 | -6.822M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-49.10M
Minimum
Mar 2023
-6.324M
Maximum
Sep 2020
-25.18M
Average
-26.76M
Median
Jun 2022
Cash from Operations (Quarterly) Benchmarks
| Acorda Therapeutics Inc | -3.018M |
| Eli Lilly and Co | 1.166B |
| Beam Therapeutics Inc | -99.75M |
| Intellia Therapeutics Inc | -93.05M |
| Gritstone Bio Inc | -19.51M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -41.63M |
| Cash from Financing (Quarterly) | 22.73M |
| Free Cash Flow | -149.88M |
| Free Cash Flow Per Share (Quarterly) | -0.5234 |
| Free Cash Flow to Equity (Quarterly) | -43.52M |
| Free Cash Flow to Firm (Quarterly) | -43.52M |
| Free Cash Flow Yield | -34.39% |